The current pricing system and fixed exchange rate policy in Turkey affect adversely market access of innovative drugs. The budget impact of innovative drugs creates an important concern to the payer perspective. Therefore, expectation of discount above the standard exposes companies to demands that cannot be fulfilled. Another important concern for companies is the parallel trade especially resulting from pricing system and fixed exchange rate policy.

OMEGA-APC, provides consultancy service on the development of alternative study models which will positively support the reimbursement evaluation decisions of innovative drugs, which are compliance with the regulatory, applicable, having proven efficacy, and in which the public and the company can benefit together.

Consultancy service in which disease, indication and product-based models are developed consists of 3 Phases;

• Phase I: Analysis
• Phase II: Model Design
• Phase III: Model Presentation and Development of Contract